Tony Berberabe, M.P.H.

Jaypirca showed superior progression-free survival and lower discontinuation rates versus standard treatments in patients with previously treated CLL or SLL.

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived without signs of cancer.

Molecular minimal residual disease status may offer clues as to which patients with acute monocytic leukemia will benefit from certain therapies.

Patients with ER-positive, HER2-negative, ESR1-mutant advanced breast cancer experienced improvements in progression-free survival when being treated with Orserdu, study results showed.

Patients with inactive early-stage chronic lymphocytic leukemia may benefit from a wait-and-watch approach compared with immediate treatment with Imbruvica, findings from a phase 3 trial showed.

Patients with pretreated metastatic colorectal cancer had better outcomes when Avastin was added to their Lonsurf treatment in the third line setting.

The use of pyrotinib — an experimental drug — plus the chemotherapy capecitabine extended survival compared with Tykerb and capecitabine among patients with pretreated HER2-positive metastatic breast cancer.

The group came together to discuss gaps in knowledge concerning the prostate cancer journey, including nonmetastatic castration-resistant prostate cancer (nmCRPC) and metastatic disease.

Axicabtagene ciloleucel can lead to complete remission for patients with refractory diffuse large B-cell lymphoma, according to a recent study.

Three treatment options for localized prostate cancer all showed a similar low prostate-specific mortality rate.

A computer simulation tool may help plan treatment for certain patients with recurrent glioblastoma.

Choosing active surveillance did not increase stress levels for men with low-risk prostate cancer, according to a recent study.

Researchers are hopeful about the potential for a novel agent in high-risk prostate cancer.

Temozolomide may have survival benefits for certain patients with brain cancer, according to a recent study.

Tecentriq is showing reduction in tumor size for patients with metastatic urothelial carcinoma, according to a phase 2 study.

New diagnoses of prostate cancer have declined nearly 30 percent, a study has found, since the U.S. Preventive Services Task Force discouraged the routine use of prostate-specific antigen testing in 2011.

Adding the chemotherapy docetaxel to standard combination hormonal and radiation therapy boosted survival rates in patients with high-risk localized prostate cancer, according to a study.

The combination of multiparametric MRI with a fusion-guided biopsy (MRI plus ultrasound) was more effective at detecting aggressive prostate cancer compared with either procedure alone.

Although use of robotic surgery for prostate cancer has surpassed open surgical procedures in number, the impact of this approach on patient quality of life has not been well-studied.

Treatment with Xtandi reduced the risk of progression by 76 percent compared with bicalutamide in men with castration-resistant prostate cancer, according to topline results from the phase 2 STRIVE study.

Two studies investigating Xtandi in men with early-stage metastatic castration-resistant prostate cancer (mCRPC) further confirmed the overall survival (OS) and progression-free survival (PFS) benefit of the agent over placebo, according to two recent studies.

The continuing contentious debate about screening for prostate cancer remains top of mind among the public and lay press.

ASCO has endorsed new prostate cancer survivorship care guidelines from the American Cancer Society that provide a structure to help prostate cancer patients with localized disease to receive high quality care from specialists and primary care physicians.